Invention Grant
US09409909B2 N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides
有权
N-（2-（杂芳基）芳基）芳基磺酰胺和N-（2-（芳基）杂芳基）芳基磺酰胺
- Patent Title: N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides
- Patent Title (中): N-（2-（杂芳基）芳基）芳基磺酰胺和N-（2-（芳基）杂芳基）芳基磺酰胺
-
Application No.: US14446127Application Date: 2014-07-29
-
Publication No.: US09409909B2Publication Date: 2016-08-09
- Inventor: Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Edward J. Sullivan , William D. Thomas , Solomon Ungashe , Penglie Zhang , Jay Powers , Sreenivas Punna
- Applicant: ChemoCentryx, Inc.
- Applicant Address: US CA Mountain View
- Assignee: ChemoCentryx, Inc.
- Current Assignee: ChemoCentryx, Inc.
- Current Assignee Address: US CA Mountain View
- Agency: Brinks Gilson & Lione
- Agent Ryan L. Marshall
- Main IPC: C07D213/02
- IPC: C07D213/02 ; C07D473/00 ; C07D209/08 ; C07D231/12 ; C07D231/14 ; C07D231/16 ; C07D231/56 ; C07D233/61 ; C07D235/06 ; C07D235/08 ; C07D249/06 ; C07D249/18 ; C07D401/04 ; C07D401/14 ; C07D403/06 ; C07D413/04 ; C07D413/14 ; C07D417/04 ; C07D471/04 ; C07D487/04 ; A61K31/404 ; A61K31/415 ; A61K31/4164 ; A61K31/4192 ; A61K31/437 ; A61K31/496 ; A61K31/52 ; A61K31/5377 ; A61K45/06
Abstract:
Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
Public/Granted literature
- US20150018337A1 N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES Public/Granted day:2015-01-15
Information query
